Loading...
•
Dec 31, 2025
Maravai Q4 2025 Earnings Report
Maravai reported fourth quarter 2025 financial results, highlighting a return to positive adjusted EBITDA and the completion of organizational restructuring.
Key Takeaways
Maravai reported Q4 revenue of $49.9 million, a decrease of 11.8% year-over-year, primarily due to lower high-volume CleanCap orders. Despite a net loss of $63.0 million, the company achieved a positive Adjusted EBITDA of $0.5 million, signaling improved operating leverage following its cost reduction initiatives.
Quarterly revenue reached $49.9 million, exceeding internal expectations despite an 11.8% year-over-year decline.
Returned to positive Adjusted EBITDA of $0.5 million in Q4, compared to a loss of $1.1 million in the prior year period.
TriLink segment revenue (formerly Nucleic Acid Production) fell 17.4% due to lower vaccine-related CleanCap volume, though base business grew 25.4%.
Introduced full-year 2026 revenue guidance of $200 million to $210 million, indicating a return to annual growth.
Revenue by Segment
Forward Guidance
Maravai introduced full-year 2026 guidance focusing on revenue growth and EBITDA expansion.
Positive Outlook
- Full year 2026 revenue expected between $200 million and $210 million.
- Adjusted EBITDA expected to be positive between $18 million and $20 million.
- Operational excellence initiatives expected to drive further operating leverage.
- Strong growth in TriLink base business (excluding high-volume CleanCap).
- Continued strength in Cygnus HCP kits from core customers.
Challenges Ahead
- Uncertainty regarding the duration of high-volume CleanCap sales for commercial vaccines.
- Potential for significant fluctuations in quarterly operating results.
- Dependency on a limited number of customers for a high percentage of revenue.
- Risks associated with recent organizational changes and workforce reductions.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...